Until this latest episode, I was on the verge of taking a small position in NSTK based, in part, on the FDA’s consenting to an abbreviated 505(b)(2) timeline for intranasal PTH. But, now, my sentiment toward the company has turned negative again. I don’t see why I should entrust my money to a company where management allows the CEO to front run shareholders so blatantly.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”